Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring

Overview of attention for article published in Frontiers in endocrinology, July 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 34,364 followers.

Frontiers | Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring https://t.co/9PjLyy29Nv

23 Jul 2023

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in…

04 Jul 2023

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in…

03 Jul 2023

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in…

03 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.